Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2020-11-03. The firm's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Follow-Up Questions
Prostatype Genomics AB 'in CEO'su kimdir?
Fredrik Persson 2017 'den beri şirketle birlikte olan Prostatype Genomics AB 'in Chief Executive Officer 'ıdır.
PGABF hissesinin fiyat performansı nasıl?
PGABF 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
Prostatype Genomics AB için ana iş temaları veya sektörler nelerdir?
Prostatype Genomics AB Biotechnology endüstrisine ait ve sektör Health Care 'dir
Prostatype Genomics AB 'in piyasa değerlemesi nedir?
Prostatype Genomics AB 'in mevcut piyasa değerlemesi $0 'dir
